Evidence map›Paper›PMID 40055398›Full record

Trial reportScientific reports2025

Effectiveness and safety of stellate ganglion block with trioxygen autologous blood retransfusion therapy for facial postherpetic neuralgia in elderly patients.

Chan Zheng, Yuanyuan Xie, Huijuan Li, Bingchang Zhang, Sifang Chen, Wanhong Han, Jiacheng Liu, Yanyan Geng, Yaya Zhang, Zhanxiang Wang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chan Zheng *Department of Pain, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Yuanyuan Xie *Department of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Huijuan LiDepartment of Pain, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Bingchang ZhangDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Sifang ChenDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Wanhong HanDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jiacheng LiuDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yanyan GengDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. yygeng@xmu.edu.cn.
Yaya ZhangDepartment of Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. xlb121021@163.com.
Zhanxiang WangDepartment of Neurosurgery and Department of Neuroscience, Fujian Key Laboratory of Brain Tumors Diagnosis and Precision Treatment, Xiamen Key Laboratory of Brain Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. wangzx@xmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluated the efficacy and safety of stellate ganglion block (SGB) combined with trioxygen autologous blood retransfusion therapy (TABRT) in treating postherpetic neuralgia (PHN) of the head and face in elderly patients. A total of 190 patients (aged ≥ 60 years) with PHN were randomly assigned to receive either drug treatment alone (Group D, n = 40), drug treatment with SGB (Group DS, n = 52), drug treatment with TABRT (Group DT, n = 53), or drug combined SGB with TABRT (Group DST, n = 45). Key outcomes included pain visual analogue scale (VAS) scores and anxiety levels at baseline, 7 days, and 15 days post-treatment, the need for salvage analgesics, and complication rates assessed. All groups showed significant improvements in pain and anxiety, with greater reductions in the DS, DT, and DST groups compared to the drug-only group, and the combined therapy (DST) showing the most pronounced benefits. The DST group also had the highest proportion of patients not requiring rescue analgesics and the highest complete remission rate. Overall, the combination of SGB and TABRT was found to be effective and safe, offering superior therapeutic outcomes compared to single therapies for elderly patients with PHN of the head and face.

Indexed as

Autonomic Nerve BlockBlood Transfusion, AutologousNeuralgia, PostherpeticStellate GanglionAgedAged, 80 and overFemaleHumansMaleMiddle AgedPain MeasurementTreatment OutcomePostherpetic neuralgiaStellate ganglion blockTrioxygen autologous blood retransfusion therapy

Identifiers

PMID40055398
PMCPMC11889258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.